Patheon Income from Continuous Operations 2015-2017 | PTHN

Patheon income from continuous operations from 2015 to 2017. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change

Patheon Income from Continuous Operations 2015-2017 | PTHN

Patheon income from continuous operations from 2015 to 2017. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$67.5B
Zoetis (ZTS)$66B
Daiichi Sankyo, - (DSNKY)$46.3B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$31.8B
Sandoz Group AG (SDZNY)$25.5B
Summit Therapeutics (SMMT)$21B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$15.2B
United Therapeutics (UTHR)$13.6B
Neurocrine Biosciences (NBIX)$12.3B
Orion OYJ (ORINY)$10.8B
IPSEN (IPSEY)$10.4B
Madrigal Pharmaceuticals (MDGL)$7.8B
Corcept Therapeutics (CORT)$7.6B
Grifols, S.A (GRFS)$7.3B
Stevanato Group S.p.A (STVN)$6.6B
Ionis Pharmaceuticals (IONS)$6.5B
Hikma Pharmaceuticals Plc (HKMPF)$5.3B
Ono Pharmaceutical (OPHLF)$5.1B
Soleno Therapeutics (SLNO)$4.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Hypermarcas (HYPMY)$2.7B
Crinetics Pharmaceuticals (CRNX)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B
Endo (NDOI)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.7B